Drug-grapefruit juice interactions

Mayo Clinic Proceedings

Volumn 75, Issue 9, 2000, Pages 933-942

  Kane, Garvan C ^a,b   Lipsky, James J ^b,c  

^a Department of Internal Medicine ^*  (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMLODIPINE; ATORVASTATIN; BUSPIRONE; CALCIUM ANTAGONIST; CERIVASTATIN; CLARITHROMYCIN; CLONAZEPAM; CYCLOSPORIN; CYTOCHROME P450; DILTIAZEM; EBASTINE; FELODIPINE; FLURAZEPAM; INDINAVIR; MEVINOLIN; NELFINAVIR; NIFEDIPINE; NIMODIPINE; NITRENDIPINE; PRANIDIPINE; PRAVASTATIN; QUINIDINE; RITONAVIR; SAQUINAVIR; SIMVASTATIN; TACROLIMUS; TERFENADINE; TRIAZOLAM; UNINDEXED DRUG; VERAPAMIL;

BIOAVAILABILITY; BRUSH BORDER; DRUG MECHANISM; ENZYME INHIBITION; FIRST PASS EFFECT; FOOD DRUG INTERACTION; PRESCRIPTION; REVIEW;

EID: 0033831256     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/75.9.933     Document Type: Review

References (99)

1. Lesser PF. Florida grapefruit-juice developments. Presented at: FoodNews Second International Fruit-Juice Conference; October 7, 1997; Amsterdam, the Netherlands.
2. Cerda JJ, Normann SJ, Sullivan MP, et al. Inhibition of atherosclerosis by dietary pectin in microswine with sustained hypercholesterolemia. Circulation. 1994;89:1247-1253.
3. So FV, Guthrie N, Chambers AF, Moussa M, Carroll KK. Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutr Cancer. 1996;26:167-181.
4. Guthrie N, Carroll KK. Inhibition of mammary cancer by citrus flavonoids. Adv Exp MedBiol. 1998;439:227-236.
5. Bailey DG, Spence JD, Edgar B, Bayliff CD, Arnold JM. Ethanol enhances the hemodynamic effects of felodipine. Clin Invest Med. 1989:12:357-362.
6. Bailey DG, Spence JD, Munoz C, Arnold JM. Interaction of citrus juices with felodipine and nifedipine. Lancet. 1991 ;337:268-269.
7. Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG. Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine-and its potential clinical relevance. Eur J Clin Pharmacol. 1992:42:313-317.
8. Zhang QY, Dunbar D, Ostrowska A, Zeisloft S, Yang J, Kaminsky LS. Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos. 1999:27:804-809.
9. Kivisto KT, Lamberg TS, Kantola T, Neuvonen PJ. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther. 1997:62:348-354.
10. Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. BrJClin Pharmacol 1998:46:49-53.
11. Floren LC, Bekersky I, Benet LZ, et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther. 1997;62:41-49.
12. Azie NE, Brater DC, Becker PA, Jones DR, Hall SD. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther. 1998;64:369-377.
13. Lundahl J, Regardh CG, Edgar B, Johnsson G. Effects of grapefruit juice ingestion-pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol. 1997:52:139-145.
14. Rashid TJ, Martin U, Clarke H, Waller DG, Renwick AG, George CF. Factors affecting the absolute bioavailability of nifedipine. BrJ Clin Pharmacol. 1995:40:51-58.
15. Kupferschmidt HH, Fattinger KE, Ha HR, Follath F, Krahenbuhl S. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol. 1998:45:355359.
16. Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther. 1995:58:20-28.
17. Hosteller KA, Wrighton SA, Molowa DT, Thomas PE, Levin W, Guzelian PS. Coinduction of multiple hepatic cytochrome P-450 proteins and their mRNAs in rats treated with imidazole antimycotic agents. Mol Pharmacol. 1989;35:279-285.
18. Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest. 1997;99:2545-2553.
19. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents: decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos. 1997;25:1228-1233.
20. Lundahl J, Regardh CG, Edgar B, Johnsson G. Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. EurJClin Pharmacol. 1995;49:61-67.
21. Maish WA, Hampton EM, Whitsett TL, Shepard JD, Lovallo WR. Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics. Pharmacotherapy. 1996;16:1046-1052.
22. Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol. 1993;35:431-436.
23. Fuhr U, Maier A, Keller A, Steinijans VW, Sauter R, Staib AH. Lacking effect of grapefruit juice on theophylline pharmacokinetics. Ira J Clin Pharmacol Ther. 1995;33:311-314.
24. Runkel M, Tegtmeier M, Legrum W. Metabolic and analytical interactions of grapefruit juice and 1,2-benzopyrone (coumarin) in man. Eur J Clin Pharmacol. 1996;50:225-230.
25. Merkel U, Sigusch H, Hoffmann A. Grapefruit juice inhibits 7hydroxylation of coumarin in healthy volunteers. Eur J Clin Pharmacol. 1994;46:175-177.
26. Lown KS, Kolars JC, Thummel KE, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: lack of prediction by the erythromycin breath test. Drug Metab Dispos. 1994;22:947-955.
27. Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benêt LZ. Grapefruit juice activates P-glycoprotein-mediated drug transport. PharmRes. 1999; 16:478-485.
28. Kim RB, Fromm MF, Wandel C, et al. The drug transporter Pglycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998;101:289-294.
29. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal Pglycoprotein (mdrl) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther. 1997;62:248-260.
30. Yee GC, Stanley DL, Pessa LJ, et al. Effect of grapefruit juice on blood cyclosporin concentration. Lancet. 1995;345:955-956.
31. Proppe DG, Hoch ÖD, McLean AJ, Visser KE. Influence of chronic ingestion of grapefruit juice on steady-state blood concentrations of cyclosporine A in renal transplant patients with stable graft function [letter]. Br J Clin Pharmacol. 1995;39:337-338.
32. Taniguchi S, Kobayashi H, Ishii M. Treatment of psoriasis by cyclosporine and grapefruit juice [letter]. Arch Dermatol. 1996; 132:1249.
33. Emilia G, Longo G, Bertesi M, Gandini G, Ferrara L, Valenti C. Clinical interaction between grapefruit juice and cyclosporine: is there any interest for the hematologists? [letter]. Blood. 1998;91: 362-363.
34. Brunner LJ, Munar MY, Vallian J, et al. Interaction between cyclosporine and grapefruit juice requires long-term ingestion in stable renal transplant recipients. Pharmacotherapy. 1998;18:2329.
35. Majeed A, Kareem A. Effect of grapefruit juice on cyclosporine pharmacokinetics [letter]. Pediatr Nephrol. 1996;10:395-396.
36. Johnston A, Holt DW. Effect of grapefruit juice on blood cyclosporin concentration [letter]. Lancet. 1995:346:122-123.
37. Edwards DJ, Fitzsimmons ME, Schuetz EG, et al. 6',7'-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther. 1999;65:237-244.
38. Bailey DG, Arnold JM, Munoz C, Spence JD. Grapefruit juicefelodipine interaction: mechanism, predictability, and effect of naringin. Clin Pharmacol Ther. 1993;53:637-642.
39. Rau SE, Bend JR. Arnold MO, Tran LT, Spence JD, Bailey DG. Grapefruit juice-terfenadine single-dose interaction: magnitude, mechanism, and relevance. Clin Pharmacol Ther. 1997:61:401409.
40. Honig PK, Wortham DC, Lazarev A, Cantilena LR. Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine. J Clin Pharmacol. 1996;36:345-351.
41. Lundahl JU, Regardh CG, Edgar B, Johnsson G. The interaction effect of grapefruit juice is maximal after the first glass. Eur J Clin Pharmacol. 1998;54:75-81.
42. Rogers JD, Zhao J, Liu LD, et al. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy3-methylglutaryl coenzyme A reductase inhibitors. Clin Pharmacol Ther. 1999:66:358-366.
43. Veronese M, Burke J, Dorval E, Pequignot E, Waldman S, Greenberg H. Grapefruit juice (GFJ) inhibits hepatic and intestinal CYP3A4 dose-dependently [abstract]. Clin Pharmacol Ther. 2000; 67:151. Abstract PIII-37.
44. Ubeaud G, Hagenbach J, Vandenschrieck S, Jung L, Koffel JC. In vitro inhibition of simvastatin metabolism in rat and human liver by naringenin. Life Sei. 1999;65:1403-1412.
45. Miniscalco A, Lundahl J, Regardh CG, Edgar B, Eriksson UG. Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J Pharmacol ExpTher. 1992;261:1195-1199.
46. Fukuda K, Ohta T, Oshima Y, Ohashi N, Yoshikawa M, Yamazoe Y. Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics. 1997:7:391-396.
47. Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follath F. In vitro inhibition of midazolam and quinidine metabolism by flavonoids. Eur J Clin Pharmacol. 1995:48:367-371.
48. Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD. Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharmacol Ther. 1993;54:589-594.
49. Fuhr U, Kümmert AL. The fate of naringin in humans: a key to grapefruit juice-drug interactions? Clin Pharmacol Ther. 1995; 58:365-373.
50. Edwards DJ, Bernier SM. Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juice. Life Sei. 1996;59: 1025-1030.
51. Fukuda K, Ohta T, Yamazoe Y. Grapefruit component interacting with rat and human P450 CYP3A: possible involvement of nonflavonoid components in drug interaction. Biol Pharm Bull. 1997; 20:560-564.
52. Edwards DJ, Bellevue FH III, Woster PM. Identification of 6',7'dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos. 1996;24:1287-1290.
53. He K, lyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF. Inactivation of cytochrome P450 3 A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol. 1998:11:252-259.
54. Bailey DG, Dresser GK, Kreeft JH, Munoz C, Freeman DJ, Bend JR. Grapefruit juice-felodipine interaction: effect of segments and an extract from unprocessed fruit [abstract]. Clin Pharmacol Ther. 2000;67:107. Abstract PI-71.
55. Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR. Grapefruit juice-felodipine interaction: effect of naringin and 6',7'-dihydroxybergamottin in humans. Clin Pharmacol Ther. 1998;64:248-256.
56. Vanakoski J, Manila MJ, Seppala T. Grapefruit juice does not enhance the effects of midazolam and triazolam in man. Eur J Clin Pharmacol. 1996;50:501-508.
57. Bailey DG, Arnold JM, Bend JR, Tran LT, Spence JD. Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. Br J Clin Pharmacol. 1995:40:135-140.
58. Hashimoto K, Shirafuji T, Sekino H, et al. Interaction of citrus juices with pranidipine, a new 1,4-dihydropyridine calcium antagonist, in healthy subjects. Eur J Clin Pharmacol. 1998;54:753760.
59. Fuhr U, Maier-Bruggemann A, Blume H, et al. Grapefruit juice increases oral nimodipine bioavailability. Int J Clin Pharmacol Ther. 1998:36:126-132.
60. Josefsson M, Zackrisson AL, Ahlner J. Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers, Eur .1 Clin Pharmacol. 1996;51:189-193.
61. Zaidenstein R, Dishi V, Gips M, et al. The effect of grapefruit juice on the pharmacokinetics of orally administered verapamil. Eur J Clin Pharmacol. 1998;54:337-340.
62. Ptachcinski RJ, Venkatararnanan R, Burckart GJ. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinel. 1986:11:107132.
63. loannides-Demos LL, Christophidis N, Ryan P, Angelis P, Liolios L, McLean AJ. Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases. J Rheumatol. 1997; 24:49-54.
64. Ku YM, Min DI, Flanigan M. Effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: does the formulation difference matter? J Clin Pharmacol. 1998;38:959-965.
65. Keogh A, Spratt P, McCosker C, Macdonald P, Mundy J, Kaan A. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. NEnglJMed. 1995:333:628-633.
66. Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther. 1996:59:383-388.
67. Jacobsen W, Kirchner G, Hallensleben K, et al. Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin. J Pharmacol Exp Ther. 1999;291:131-139.
68. Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther. 1998:63:397-402.
69. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther. 1998:64:477-483.
70. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther. 1999;66:118-127.
71. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther. 1998;64: 58-65.
72. Corpier CL, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use: report of two cases in cardiac transplant recipients. JAMA. 1988:260:239-241.
73. Ahmad S. Diltiazem myopathy [letter]. Am Heart J. 1993:126: 1494-1495.
74. Spach DH, Bauwens JE, Clark CD, Burke WG. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med. 1991 ; 154:213-215.
75. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole [letter]. N Eng! J Med. 1995:333:664-665.
76. Schmassmann-Suhijar D, Bullingham R, Gasser R, Schmutz J, Haefeli WE. Rhabdomyolysis due to interaction of simvastatin with mibefradil [letter]. Lancet. 1998;351:1929-1930.
77. Ho PC, Chalcroft SC, Coville PF, Wanwimolruk S. Grapefruit juice has no effect on quinine pharmacokinetics. Eur J Clin Pharmacol. 1999;55:393-398.
78. Min DI, Ku YM, Geraets DR, Lee H. Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers. J Clin Pharmacol. 1996:36:469-476.
79. van Agtmael MA, Gupta V, van der Wösten TH, Rutten J-PB, van Boxtel CJ. Grapefruit juice increases the bioavailability of artemether. EurJ Clin Pharmacol. 1999;55:405-410.
80. Food and Drug Administration. Janssen Pharmaceutica stops marketing cisapride in the US. Rockville, Md: Food and Drug Administration, US Dept of Health and Human Services, Public Health Service; March 23, 2000. PDA Talk Paper TOO-14.
81. Gross AS, Goh YD, Addison RS, Shenfield GM. Influence of grapefruit juice on cisapride pharmacokinetics. Clin Pharmacol Ther. 1999:65:395-401.
82. Kivisto KT, Lilja JJ, Backman JT, Neuvonen PJ. Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. Clin Pharmacol Ther. 1999;66:448-453.
83. Pletal [package insert]. Rockville, Md: Otsuka America Pharmaceutical Inc; 1999.
84. Suri A, Forbes WP, Bramer SL. Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37(suppl 2):61-68.
85. Cheng KL, Nafziger AN, Peloquin CA, Amsden GW. Effect of grapefruit juice on clarithromycin pharmacokinetics. Antimicrob Agents Chemother. 1998;42:927-929.
86. Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H. Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects. Int J Clin Pharmacol Ther. 1998; 36:306-308.
87. Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M. Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers. Ther Drug Monit. 1999;21:304-309.
88. Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A. Interaction between grapefruit juice and diazepam in humans. EurJ Drug Metab Pharmacokinet. 1998:23:55-59.
89. Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther. 1995;58:127-131.
90. Lilja JJ, Kivisto KT, Backman JT, Lamberg TS, Neuvonen PJ. Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther. 1998;64:655-660.
91. Lee AJ, Chan WK, Harralson AF, Buffum J, Bui B-CC. The effects of grapefruit juice on sertraline metabolism: an in vitro and in vivo study. Clin Ther. 1999;21:1890-1899.
92. Garg SK, Kumar N, Bhargava VK, Prabhakar SK. Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. Clin Pharmacol Ther. 1998;64:286-288.
93. Oesterheld J, Kallepalli BR. Grapefruit juice and clomipramine: shifting metabolitic ratios [letter], J Clin Psychopharmacol. 1997; 17:62-63.
94. Weber A, Jager R, Borner A, et al. Can grapefruit juice influence ethinylestradiol bioavailability? Contraception. 1996;53:41-47.
95. Lee YS, Lorenzo BJ, Koufis T, Reidenberg MM. Grapefruit juice and its flavonoids inhibit 11 beta-hydroxysteroid dehydrogenase. Clin Pharmacol Ther. 1996;59:62-71.
96. Hollander AA, van Rooij J, Lentjes GW, et al. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. Clin Pharmacol Ther. 1995;57:318-324.
97. Hall MCS, Ahrnad S. Interaction between sildenafil and HIV-1 combination therapy [letter]. Lancet. 1999;353:2071-2072.
98. Merry C, Barry MG, Ryan M, et al. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS. 1999;13:F101-F107.
99. Curhan GC, Willett WC, Rimm EB, Spiegelman D, Stampfer MJ. Prospective study of beverage use and the risk of kidney stones. Am JEpidemiol. 1996:143:240-247.